Actively Recruiting
Evaluating Safety, Tolerability, and Efficacy of Single Intravitreal Injection of SPVN20 Gene Therapy in Adults With Advanced Rod-Cone Dystrophy
Led by SparingVision · Updated on 2026-09-08
27
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of a gene therapy called SPVN20 in adults with advanced Rod-Cone Dystrophy, a rare eye condition affecting vision. This open-label, multi-center study is a Phase IIIa trial designed to test escalating doses of SPVN20 delivered through a single injection into the eye. The trial aims to understand how well the treatment works and how safe it is for patients with this advanced retinal disease. Participants will receive a single intravitreal injection of SPVN20 in one eye. They will be assigned sequentially to one of three groups receiving low, medium, or high doses of SPVN20. Each group will include nine participants. This first-in-human study involves careful monitoring of participants over time to observe the effects of different doses and to find the best balance of safety and potential benefit. Throughout the study, participants will be followed for five years after the injection. They will undergo regular eye exams, vision tests including best corrected visual acuity and full-field stimulus threshold tests, and monitoring for any side effects or eye safety concerns. An independent committee will review safety data to ensure participant well-being. The long-term follow-up will help researchers gather detailed information about the gene therapys impact and any lasting effects.
CONDITIONS
Brief Title
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
Research Team
M
Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here